ProMIS Neurosciences Inc.: ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial
ProMIS Neurosciences (Nasdaq: PMN) reported blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial of PMN310 in 136 Alzheimer’s patients. As of the cutoff, no ARIA-E occurred and total ARIA was 4.4% (mild, asymptomatic ARIA-H only). Early biomarker shifts in pTau217 and CSF MTBR-tau243 were reported. Unblinded 12-month topline data are expected in Q1 2027.
How this was made
The 30-second read
Why it matters
The key tradable update is the interim safety profile: no ARIA-E reported and low total ARIA (all mild/asymptomatic ARIA-H), plus early directionally consistent biomarker movement (plasma pTau217 and CSF MTBR-tau243) on a blinded basis. This can shift expectations for the probability of a clean unblinding, but it does not establish efficacy.
Market read
Traders may reprice PMN’s near-to-interim risk profile based on the absence of ARIA-E and early biomarker directionality, while still waiting for unblinded 12-month topline in Q1 2027.
What to watch
ARIA risk can be time-dependent and dose-dependent; the release does not provide unblinded efficacy, dose-by-dose ARIA breakdown, or longer follow-up beyond the interim cutoff.
Background
PMN310 is a humanized IgG1 monoclonal antibody designed to bind toxic amyloid-beta oligomers while avoiding plaque, aiming to decouple efficacy from ARIA risk. PRECISE-AD is a randomized, double-blind, placebo-controlled Phase 1b trial with 12-month treatment duration.
Ticker impact
ProMIS reports blinded 6-month interim PRECISE-AD data for PMN310, including no ARIA-E cases and early biomarker declines in 136 patients.
Near-term upside bias possible on biotech sentiment, but magnitude likely capped until unblinding and 12-month efficacy data in Q1 2027.
The release is a primary clinical-trial datapoint with specific safety (no ARIA-E) and biomarker directionality, but it remains blinded and explicitly not efficacy.
Market effects
Supports the broader thesis that oligomer-selective amyloid targeting may reduce ARIA risk, potentially improving sentiment for similar Alzheimer’s antibody approaches.
Limited direct regional spillover; primarily US biotech sentiment tied to Nasdaq-listed clinical-stage names.
Alzheimer’s trial read-through may influence global investor appetite for neurodegeneration antibody platforms, though evidence is interim and blinded.
Counterpoint
Blinded biomarker directionality may reflect randomization patterns rather than treatment effect, and absence of ARIA-E at 6 months may not persist through 12 months or higher exposure.
Key entities
- companyProMIS Neurosciences Inc.
Nasdaq-listed clinical-stage biopharmaceutical company developing PMN310 for Alzheimer’s disease.
- drug_candidatePMN310
Oligomer-selective anti-amyloid-beta monoclonal antibody intended to reduce ARIA risk versus plaque-binding antibodies.
- clinical_trialPRECISE-AD
Phase 1b randomized, double-blind, placebo-controlled trial evaluating PMN310 in mild cognitive impairment due to AD or mild AD.
